Fujifilm Implements Leadership Changes to Enhance Life Sciences Capabilities

FUJIFILM Holdings America Corporation announced additional leadership responsibilities for three key leaders in its Life Sciences Group companies.

Tomoyuki Hasegawa is now CEO of FUJIFILM Biotechnologies California, a global CDMO for biologics and advanced therapies. He also continues to serve as general manager of Fujifilm Life Sciences Strategic Office, and chairman/CEO of FUJIFILM Cellular Dynamics, a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs).

For the last four years, Hasegawa has led FUJIFILM Cellular Dynamics’ advances in regenerative medicine and life sciences, helping build technologies and partnerships. He has been with Fujifilm for more than 25 years, serving in several leadership roles throughout the company, both in Japan and the United States.

In June, he supervised the opening of FUJIFILM Cellular Dynamics’ new headquarters and iPSC development and manufacturing facility in Madison, Wis. The new site serves the company’s iPSC-based research products and services, expanding the manufacturing footprint and development capabilities across FUJIFILM Cellular Dynamics’ portfolio. The company’s iPSC-derived iCell product lines are increasingly leveraged for New Approach Methods (NAMs) in drug discovery.

Delara Motlagh, chief operating officer of FUJIFILM Cellular Dynamics, is also serving as its president, assuming additional responsibilities for overseeing the business. Since joining the company in April 2025, Motlagh has overseen business, strategy, and execution across FUJIFILM Cellular Dynamics’ discovery research and cell therapy CDMO business units globally.

Motlagh has more than two decades of industry experience spanning life sciences, strategic leadership, and deep expertise in cell and gene therapy. Before joining FUJIFILM Cellular Dynamics, she held senior leadership positions at Catalent Pharma Solutions, Terumo Blood and Cell Technologies, and Baxter Healthcare, with a track record across business strategy, commercial, operations, R&D, and marketing.

In his new role, Hasegawa will work with FUJIFILM Biotechnologies California’s newly appointed Chief Operating Officer David Bolish, to strengthen Fujifilm’s cell therapy CDMO offerings. Bolish has been site head since 2018, with more than 20 years of experience overall in biopharmaceutical manufacturing, engineering, product commercialization, and strategy.

“As one of Fujifilm’s most experienced leaders, Tom is positioned to align our cell therapy offerings across two complementary businesses, thus supporting a truly robust end-to-end cell therapy CDMO experience for our partners,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation. “Delara’s leadership at FUJIFILM Cellular Dynamics comes at a critical time, with growing demand for New Approach Methodologies (NAMs) and a need for experienced iPSC partners in therapeutic development. These organizational enhancements are a further investment in scaling Fujifilm’s infrastructure to support the next generation of cell-based research and therapeutics in the U.S. With their experience in cell therapy and commitment to making a difference in patients’ lives, these three leaders will continue to drive the ‘Partners for Life’ approach of our Fujifilm Life Sciences Group companies.”

FUJIFILM Biotechnologies California, a subsidiary of FUJIFILM Corporation, specializes in developing and manufacturing cell-based therapeutics. Located in Thousand Oaks, Calif., the company operates a state-of-the-art cell therapy manufacturing facility featuring cGMP production suites, quality control and development laboratories, and product storage and distribution capabilities. These facilities support both autologous and allogeneic cell therapy manufacturing while meeting global regulatory standards for advanced therapies and medicinal products. With its workforce and regulatory agency-approved manufacturing capabilities, FUJIFILM Biotechnologies California is shaping the future of medicine through the advanced production of cell therapies. The company leverages the global network and end-to-end CDMO capabilities of the Fujifilm Life Sciences Group to provide solutions that support complex cell therapy development and manufacturing.

FUJIFILM Cellular Dynamics, Inc. is a developer and manufacturer of human iPSCs and iPSC-derived cells utilized in drug discovery, contract development, and manufacturing services for cell therapies. For its partners, FUJIFILM Cellular Dynamics utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FUJIFILM Cellular Dynamics also offers life science research tools including the company’s inventoried iCell products.

FUJIFILM Americas is the regional headquarters for the Americas. It is comprised of 20 group companies across North and Latin America that are engaged in the research, development, manufacture, sale, and service of Fujifilm products and services. The company’s portfolio represents a broad spectrum of industries including medical and life sciences, electronic materials, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography.

FUJIFILM Holdings Corporation, headquartered in Tokyo, delivers products and services globally through the four key business segments of healthcare, electronics, business innovation, and imaging, with more than 70,000 employees. Under its medium-term management plan, VISION2030, which ends in fiscal year 2030, the company aspires to become an organization that creates value for various stakeholders and achieves 4 trillion yen in revenue ($29 billion at an exchange rate of 140 yen to the dollar).